US · Healthcare · Biotechnology
EPS came in at -0.93 against a street estimate of -0.77 — a miss of 20.8%.
Analysts rate MoonLake Immunotherapeutics a buy (11 buy, 2 hold, 2 sell out of 15) with an average price target of $28.54.
| Fund | Stake |
|---|---|
| Bvf Inc | 18.80% |
| Deep Track Capital, LP | 8.22% |
| T. Rowe Price Investment Management,Inc. | 5.03% |
| D. E. Shaw & Co LP | 3.95% |
| Cormorant Asset Management, LLC | 3.77% |
| Jupiter Topco LLC | 3.63% |
| Logos Global Management LP | 3.14% |
| Weiss Asset Management LP | 3.03% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on sonelokimab, a single drug candidate targeting in | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash, cash equivalents and short-term marketable debt securities totaled $498.5 million as of September 30, 2026. • MoonLake expe | 2026-11-04 |
| Company announcement · Q3 2026 HEADLINE NUMBERS • On September 30, 2026, MoonLake Immunotherapeutics submitted a Biologics License Application (BLA) to the U.S. FDA. • The applica | 2026-09-30 |
| Quarterly report · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $477.9 million in cash and cash equivalents plus $59.1 million | 2026-08-10 |
| Results announced · Q3 2026 MOONLAKE IMMUNOTHERAPEUTICS - INVESTOR SUMMARY HEADLINE NUMBERS • Cash Position: $537.0 million in cash, cash equivalents and short-term marketable | 2026-08-10 |
| Company announcement · Q3 2026 MOONLAKE IMMUNOTHERAPEUTICS - FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed exercise of underwriter option to purchase 1,500,000 additional | 2026-07-15 |
| Material agreement · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS - FORM 8-K SUMMARY HEADLINE NUMBERS • Company conducting public offering of 9,000,000 Class A ordinary shares at $20.00 | 2026-06-25 |
| Reg FD disclosure · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced Week 52 results from Phase 3 VELA clinical trials (VELA-1 and VE | 2026-06-22 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MoonLake Immunotherapeutics — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.